KeyMed Biosciences Inc
F:64Z
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
KeyMed Biosciences Inc
F:64Z
|
CN |
|
B
|
Blackstone Inc
F:BBN1
|
US |
|
S
|
Schlumberger NV
F:SCL
|
US |
|
Galapagos NV
AEX:LKFT
|
BE |
|
Smartfit Escola de Ginastica e Danca SA
OTC:SFEGY
|
BR |
|
C
|
China Merchants Bank Co Ltd
XMUN:M4B
|
CN |
|
H
|
Hisamitsu Pharmaceutical Co Inc
OTC:HTSUF
|
JP |
|
D
|
Deutsche Bank AG
F:DBK
|
DE |
|
Investec Ltd
F:IYYA
|
ZA |
|
H
|
Holcim AG
XHAM:HLBN
|
CH |
|
Ryanair Holdings PLC
XETRA:RY4C
|
IE |
|
Z
|
Zions Bancorporation NA
XBER:ZB1
|
US |
|
SGS SA
F:SUVN
|
CH |
|
C
|
China State Construction International Holdings Ltd
XMUN:C4S1
|
HK |
KeyMed Biosciences Inc
KeyMed Biosciences is a drug developer focused on antibody medicines. It builds biologic therapies, especially monoclonal and bispecific antibodies, aimed at diseases such as cancer and autoimmune disorders. The company does not sell ordinary consumer products; its work is in turning lab-made antibodies into prescription medicines that can be tested, approved, and used by doctors and hospitals. Its main customers are pharmaceutical partners, healthcare providers, and ultimately patients who receive its medicines. KeyMed can make money in a few ways: by licensing drug candidates to partners, by receiving milestone and royalty payments when those drugs advance or sell, and by selling its own approved products if and when they reach the market. In this industry, the value comes from owning the science, patents, and development know-how behind the drug. What makes KeyMed’s business model different is that it sits at the high-risk, high-reward end of biotech. It spends years developing specific antibody drugs, often for hard-to-treat conditions, and depends on successful clinical testing and regulatory approval before those programs can become meaningful revenue sources. That makes it more of a pipeline-driven drug creator than a broad pharmaceutical seller.
KeyMed Biosciences is a drug developer focused on antibody medicines. It builds biologic therapies, especially monoclonal and bispecific antibodies, aimed at diseases such as cancer and autoimmune disorders. The company does not sell ordinary consumer products; its work is in turning lab-made antibodies into prescription medicines that can be tested, approved, and used by doctors and hospitals.
Its main customers are pharmaceutical partners, healthcare providers, and ultimately patients who receive its medicines. KeyMed can make money in a few ways: by licensing drug candidates to partners, by receiving milestone and royalty payments when those drugs advance or sell, and by selling its own approved products if and when they reach the market. In this industry, the value comes from owning the science, patents, and development know-how behind the drug.
What makes KeyMed’s business model different is that it sits at the high-risk, high-reward end of biotech. It spends years developing specific antibody drugs, often for hard-to-treat conditions, and depends on successful clinical testing and regulatory approval before those programs can become meaningful revenue sources. That makes it more of a pipeline-driven drug creator than a broad pharmaceutical seller.
